Synthekine
Menlo Park
About Synthekine
Synthekine is an engineered cytokine therapeutics company that creates selective immunotherapies to improve cancer and inflammatory disease treatment paradigms. Using knowledge of cytokine structure and function, the company develops therapeutics that maximize cytokine efficacy while avoiding toxic side effects. Synthekine is developing a broad and deep pipeline of product candidates by leveraging principles of cytokine partial agonism and immunological specificity across multiple protein engineering platforms. Modified cytokines, cytokine-enhanced cell therapies, and surrogate cytokine agonists are among the novel immunotherapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $289.5M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2023)
- Website: synthekine.com
- Phone: (650) 271-9888
Industries & Categories
Biotechnology, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/synthekine-43209 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.